PROF — Profound Medical Corp
NASDAQ · Healthcare · Medical Devices
$6.93
+$0.13 (+1.91%)
Profound Medical Corp (PROF) is a medical devices company listed on NASDAQ. It is led by Arun Swarup Menawat MBA, Ph.D., based in 2400 Skymark Avenue, Mississauga, ON, Canada, L4W 5K5, with about 162 employees. Profound Medical Corp. operates as a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapeutic systems for the image guided ablation of diseased tissue. The company's lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. It also provides Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. It operates in Canada, Germany, the United States, China, and Finland. Profound Medical Corp. is headquartered in Mississauga, Canada.
Latest reported PROF revenue for 2025-09-30 was $5.3M. Net income was -$34.4M. Revenue was up 139.2% from 2025-06-30 to 2025-09-30. PROF currently screens at market cap $238.7M.
Use this PROF page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the PROF quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the PROF SEC filings page. Lician reads the product cache first so this HTML stays unique to Profound Medical Corp even when a live quote feed is slow.
About Profound Medical Corp
Profound Medical Corp. operates as a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapeutic systems for the image guided ablation of diseased tissue. The company's lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. It also provides Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. It operates in Canada, Germany, the United States, China, and Finland. Profound Medical Corp. is headquartered in Mississauga, Canada.
PROF Key Statistics
Market Cap
$238.74M
Volume
2,366
Previous Close
$6.85
Day Range
$6.72 – $6.99
P/B Ratio
4.05
EPS
$1.12
Revenue
$10.68M
Net Income
-$27.82M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+48.4%
Profit Margin
-260.4%
Employees
162
PROF Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 |
|---|---|---|
| Revenue | $10.68M | $7.20M |
| Cost of Revenue | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 |
| Net Income | -$27.82M | -$28.32M |
| EPS (Diluted) | $1.12 | $1.34 |
Total Assets
$70.23M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$54.91M
Operating Cash Flow
-$23.45M
Free Cash Flow
$0.00
Profound Medical Corp Company Information
- Chairman of the Board & CEO
- Arun Swarup Menawat MBA, Ph.D.
- Headquarters
- 2400 Skymark Avenue, Mississauga, ON, Canada, L4W 5K5
- Website
- www.profoundmedical.com
- Phone
- 647 476 1350
- IPO / Founded
- 2016-06-09
- Sector
- Healthcare
- Industry
- Medical Devices